Satoshi Yamasaki

Satoshi Yamasaki

Auto-generated profile, based on publicly available information

Satoshi Yamasaki

Department of Clinical Cancer Genomics, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
HKHiroshi Kagamu
Hiroshi Kagamu
SYSatoshi Yamasaki
Satoshi Yamasaki
SKShigehisa Kitano
Shigehisa Kitano
OYOu Yamaguchi
Ou Yamaguchi
AMAtsuto Mouri
Atsuto Mouri
KHKatsuhisa Horimoto
Katsuhisa Horimoto
CD4+ T-cell immunity helps clonal proliferation, migration, and cancer cell killing activity of CD8+ T cells and is essential in antitumor immune responses. To identify CD4+ T-cell clusters responsible for antitumor immunity, we simultaneously analyzed the naïve-effector state, Th polarization, and T-cell receptor clonotype based on single-cell RNA-sequencing data. Unsupervised clustering analysis uncovered the presence of a new CD4+ T-cell metacluster in the CD62Llow CD4+ T-cell subpopulation, which contained multicellular clonotypes associated with efficacy of programmed death-ligand 1 (PD-1) blockade therapy. The CD4+ T-cell metacluster consisted of CXCR3+CCR4−CCR6+ and CXCR3−CCR4−CCR6+ cells and was characterized by high expression of IL7 receptor and TCF7. The frequency of these cells in the peripheral blood significantly correlated with progression-free survival and overall survival of patients with lung cancer after PD-1 blockade therapy. In addition, the CD4+ metacluster in the peripheral blood correlated with CD4+ T-cell infiltration in the tumor microenvironment, whereas peripheral Th1 correlated with local CD8+ T-cell infiltration. Together, these findings suggest that CD62Llow CCR4−CCR6+ CD4+ T cells form a novel metacluster with predictive potential of the immune status and sensitivity to PD-1 blockade, which may pave the way for personalized antitumor immunotherapy strategies for patients. Significance: The identification of a new CD4+ T-cell metacluster that corresponds with immune status could guide effective tumor treatment by predicting response to immunotherapy using peripheral blood samples from patients.

19 July 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
AYAkitoshi Yanagihara
Akitoshi Yanagihara
SYSatoshi Yamasaki
Satoshi Yamasaki
KHKosuke Hashimoto
Kosuke Hashimoto
RTRyo Taguchi
Ryo Taguchi
TUTetsuya Umesaki
Tetsuya Umesaki
HKHiroshi Kagamu
Hiroshi Kagamu
Perioperative immune checkpoint inhibitors have been shown to improve prognosis in early-stage lung cancer. However, no biomarkers are known to indicate the requirement for treatment. This study aimed to identify T-cell clusters responsible for antitumor immunity in patients with early-stage lung cancer. Preoperative blood samples from 50 consecutive patients with lung cancer who were diagnosed as operable and underwent complete resection were analyzed by mass cytometry. Patients were divided into two groups: no recurrence at a minimum observation period of 851 days (median observation period: 1,031.5 days) and recurrence by the last observation date. Mass cytometry and single-cell RNA sequencing analysis of lymph nodes (LN) and tumor-infiltrating T cells were also performed. CCR4−CCR6+ Th7R showed discriminative ability between recurrence and non-recurrence patients with lung cancer. Patients with more than 3.04% Th7R showed significantly favorable disease-free survival. Th7R was a major component of CD4+ T cells in tumor microenvironments and LNs adjacent to lung cancer tissues and was the only cluster that decreased in peripheral blood after the removal of cancer tissues, suggesting that Th7R was primed and proliferated in tumor-draining LNs in the presence of cancer tissues. Th7R had the kinetics that antitumor T cells should have, as indicated by the cancer immunity cycle; thus, peripheral blood Th7R could represent the potency of tumor immunity by reflecting priming and proliferation in tumor-draining LNs and Th7R in the tumor microenvironment. Prediction using peripheral Th7R before surgery could allow the selection of patients who require perioperative drug therapy and optimize therapeutic interventions with clinical implications. Significance: Peripheral Th7R, a Th1-like CD4+ T-cell cluster reflecting priming status in draining LNs and immune status in the tumor microenvironment, predicts disease-free survival after complete resection and has significant clinical relevance in selecting appropriate therapeutic interventions in patients with early-stage lung cancer.

28 March 2026 in Nature Communications
Verified
Journal Article
Open access
STShota Takei
Shota Takei
SYSatoshi Yamasaki
Satoshi Yamasaki
OYOu Yamaguchi
Ou Yamaguchi
AMAtsuto Mouri
Atsuto Mouri
ASAyako Shiono
Ayako Shiono
HKHiroshi Kagamu
Hiroshi Kagamu
CD4⁺ T cells support the priming, expansion, and function of CD8⁺ T cells through dendritic cells. Precursor exhausted T cells (Tpex) maintain self-renewal and supply cytotoxic CD8⁺ T cells in the tumor microenvironment (TME), but the identity of their CD4⁺ T-cell partners remains unclear. Here, we perform scRNA-seq, scTCR-seq, and mass cytometry analysis on peripheral blood, tumor, and lymph nodes primarily from lung cancer patients and, in part, renal cell carcinoma. We identify an IL-7Rhigh CCR6⁺ Th1-like CD4⁺ T cell-population, named Th7R, that is numerically and spatially partnered with Tpex. Th7R cells express lymphotoxin-β and CXCL13, correlate with high endothelial venules, and co-localize with Tpex in tertiary lymphoid structures. Th7R cell abundance correlates with Tpex numbers in the TME and lymph nodes, and adoptive transfer of Th7R increases Tpex in a preclinical mouse model. Intratumoral Th7R and Tpex associate with improved response to neoadjuvant PD-1 blockade therapy. These results suggest that Th7R cells act as partners of Tpex to sustain antitumor T-cell immunity.

24 November 2025
Verified
Other
Open access
HKHiroshi Kagamu
Hiroshi Kagamu
SYSatoshi Yamasaki
Satoshi Yamasaki
SKShigehisa Kitano
Shigehisa Kitano
OYOu Yamaguchi
Ou Yamaguchi
AMAtsuto Mouri
Atsuto Mouri
KHKatsuhisa Horimoto
Katsuhisa Horimoto
Supplementary Table 2, 4, 5, 6, 7.


31 March 2023
Verified
Other
Open access
HKHiroshi Kagamu
Hiroshi Kagamu
SYSatoshi Yamasaki
Satoshi Yamasaki
SKShigehisa Kitano
Shigehisa Kitano
OYOu Yamaguchi
Ou Yamaguchi
AMAtsuto Mouri
Atsuto Mouri
KHKatsuhisa Horimoto
Katsuhisa Horimoto
Supplementary Table 2, 4, 5, 6, 7.